Sorry, you need to enable JavaScript to visit this website.

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign-up to receive all GMG announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts
Title
Grant Type
Focus Area
Country
Application Due Date
Research in Ulcerative Colitis (UC) 2024
Release Date:
Review Process: Expert Review Panel
Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Research Oncology USA
BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Translation: Japanese (link)
Education Oncology Japan
Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophilia
Release Date:
Review Process: Pfizer Internal
Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom
Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)
Release Date:
Review Process: Pfizer Internal
Education Rare Disease All
Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)
Release Date:
Partner: Sumitomo Pharma
Review Process: Pfizer Internal
Education Oncology USA
Title
Grant Type
Focus Area
Country
Application Due Date
Hemophilia Research in Africa-Middle East, Asia Pacific, China and Latin America
Release Date:
Review Process: Expert Review Panel
Research Rare Disease All
Rheumatic diseases such as SLE, SS, SSc, vasculitis syndrome
Release Date:
Review Process: Pfizer Internal
Education Inflammation & Immunology Japan
Optimal treatment and management of Rheumatoid Arthritis
Release Date:
Review Process: Pfizer Internal
Education Inflammation & Immunology Japan
Education relating to Etiology, diagnosis, treatment and, management of Spondyloarthritis
Release Date:
Review Process: Pfizer Internal
Education Inflammation & Immunology Japan
Inflammation ASPIRE Rheumatology: Europe (except Germany), Israel, Turkey, Russia, Australia, New Zealand, Japan and South Korea
Release Date:
Review Process: Expert Review Panel
Research Inflammation & Immunology All
Inflammation ASPIRE Ulcerative Colitis:Europe (except Germany), Israel, Turkey,Russia,Australia,New Zealand, Japan, South Korea
Release Date:
Review Process: Expert Review Panel
Research Inflammation & Immunology All
Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis
Release Date:
Review Process: Expert Review Panel
Quality Improvement Rare Disease All
Hemophilia: Improve general knowledge level of gene therapy
Release Date:
Review Process: Pfizer Internal
Education Rare Disease Japan
Providing Enhanced Medical Support for Patients with Primary Immunodeficiency (PI) Disorders
Release Date:
Review Process: Pfizer Internal
Education Internal Medicine USA
Serotyping of Streptococcus pneumoniae
Release Date:
Review Process: Pfizer Internal
Education Vaccines Japan
Artificial Intelligence/Machine Learning Research in Hemophilia
Release Date:
Review Process: Expert Review Panel
Research Rare Disease USA
Education of Healthcare Professionals to Provide Appropriate Medical Care for IBD Patients
Release Date:
Review Process: Pfizer Internal
Education Inflammation & Immunology Japan